Feb 3, 2023 | Alternative Reimbursement Strategies, Claims, Cost Savings, Direct-to-Employer Contracting, Drug costs, Forensic claims review, Gene therapy, Health care costs, Inflation, MedBen Rx, MedBen WellLiving, Prescription, Rx Costs, Savings, Specialty Drugs, Wellness
Even though health care costs have not seen the same rate of inflation as other industries, that’s about to change. Fortunately, MedBen has a variety of inflation-hedging solutions to counter rising costs. As a recent Self-Insurer article notes, health care...
Jan 6, 2023 | Drug costs, Drugmakers, News, Prescription, Rx Costs
From Reuters: “Drugmakers including Pfizer Inc, GlaxoSmithKline PLC, Bristol Myers Squibb, AstraZeneca PLC and Sanofi SA plan to raise prices in the United States on more than 350 unique drugs in early January, according to data analyzed by healthcare research...
Dec 27, 2022 | Alternative Reimbursement Strategies, Client Surveys, Kurt Harden, MedBen Rx, Prescription, Reference-Based Pricing, Regulatory
On behalf of our entire team, I wish you a Happy New Year and thank you for your continued business with MedBen. We often say that “MedBen Delivers,” and it’s a statement that covers a variety of factors such as plan design strategies, claims processing accuracy, and...
Dec 22, 2022 | Lobbying, Pharmacy Benefits Manager (PBM), Prescription, Spending
A review of the biggest spenders in health care lobbying by OpenSecrets reveals that, in the leadup to the 2021-22 election cycle, 16 of the top 25 lobbyists were pharmaceutical & health product organizations (see table below). The top health care lobbyist,...
Dec 12, 2022 | Drug costs, Gene therapy, MedBen Rx, Prescription
The Self-Insurer magazine recently examined the emergence of innovative gene therapies that carry substantial benefits… and hefty price tags. The FDA just approved a hemophilia B gene therapy that costs $3.5 million a dose, making it the world’s most...
Dec 8, 2022 | Diabetes, Obesity, Prescription
The latest “Hollywood weight-loss drug” has generated interest for its pound-shedding potential, but doctors caution that its benefits should be measured against other factors. Approved by the FDA in 2017 for type 2 diabetes treatment, Semaglutide...
